nimotuzumab
biocon,daiichi sankyo,oncoscience
['improve', 'nimotuzumab', 'pancreatic']
nimotuzumab plus gemcitabine improves survival in kras wild-type pancreatic cancer #asco22
SVP, Content @MJHLifeSciences. Focused on creating innovative, expert-driven content @OncLive @MedEconomics @AJMC_Journal @Pharmacy_Times @MDMagazine plus more